All In Biotech

Drug Trial Radar · NCT06099184

Study of EYP-1901 in Patients With Diabetic Macular Edema (DME)

A Phase 2, Multicenter, Prospective, Randomized, Double-Masked, Parallel Study of EYP-1901, a Tyrosine Kinase Inhibitor (TKI), Compared to Aflibercept in Subjects With Diabetic Macular Edema (DME)

Last checked: Nov 20, 2026Latest source record: Mar 4, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

27

Actual

Start

Jan 15, 2024

Primary completion

Oct 24, 2024

Study completion Oct 24, 2024

Sponsor

Lead sponsor
EyePoint Pharmaceuticals, Inc.Industry
Sponsor type
Industry
First posted
Oct 25, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Single (participant)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A prospective, randomized, single-masked study evaluating the ocular efficacy and safety of two doses of the EYP-1901 intravitreal insert compared to aflibercept

Conditions

  • Diabetic Macular Edema

Interventions

  • EYP-1901Drug

    Intravitreal Injection

  • Aflibercept 2Mg/0.05Ml Inj,OphDrug

    Intravitreal Injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time to first supplemental aflibercept injection following EYP-1901 dose at Baseline vs AfliberceptTime frame: Week 24

Locations

6 sites in 1 country. Site status is shown where the registry gives one.

  • EyePoint Investigative Site

    Phoenix, Arizona

  • EyePoint Investigative Site

    Lemont, Illinois

  • EyePoint Investigative Site

    Hagerstown, Maryland

  • EyePoint Investigative Site

    Reno, Nevada

  • EyePoint Investigative Site

    Erie, Pennsylvania

  • EyePoint Investigative Site

    Lynchburg, Virginia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.